Legend Biotech Receivables

Legend Biotech (LEGN) currently reports a receivables of $190M as of March 2026. That compares with $170M in the prior-year period — up 11.8% year over year. Use the charts on this page to explore Legend Biotech's receivables history and peer comparisons.

Legend Biotech's receivables increased from $170M to $190M — a 11.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Legend Biotech reported $190M in receivables as of March 2026. That compares with $170M in the prior-year period — up 11.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Legend Biotech, and consider following LEGN for alerts when major investors trade the stock.

Legend Biotech is classified in the Healthcare sector. On receivables, it currently shows $190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LEGN with unrelated industries.